Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized

KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.

Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC

The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.



Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC

Clinical outcomes did not significantly differ with atezolizumab plus bevacizumab vs tremelimumab and durvalumab in treatment-naive, unresectable HCC. 

 Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia. 

Venetoclax Elicits Immune Synapse Repair in Chronic Lymphocytic Leukemia

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Envafolimab plus suvemcitug and FOLFIRI demonstrated preliminary activity and tolerability in second-line MSS/pMMR CRC.

Envafolimab Plus Suvemcitug and FOLFIRI Shows Early Efficacy, Tolerability in Second-Line CRC

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Adam Duvall, MD, MPH, spotlights new research further elucidating the role of blinatumomab in the acute lymphoblastic leukemia treatment paradigm.

Emerging Data Continue to Shape the Role of Blinatumomab in Acute Lymphoblastic Leukemia 

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.

NX-5948 Demonstrates Preliminary Efficacy in High-Risk CLL 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

1rem

primary

View

ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care  

Video Series

OncLive Peer Exchange® 

JAK Inhibition in Polycythemia Vera: Treatment Updates

Video content above is prompted by the following:

How would you describe the role of JAK inhibition for patients with PV?

Please comment on the latest efficacy data of ruxolitinib (RUX) in PV.

Videos

Panelists discuss how recent advancements in the treatment of polycythemia vera and myelofibrosis, including the role of JAK inhibitors, cytoreductive therapy, and emerging therapies, are shaping current clinical practice and guiding personalized treatment strategies.

Panelists discuss how they approach the evaluation and diagnosis of polycythemia vera (PV), including key clinical manifestations, and how they assess disease risk to determine initial treatment strategies based on NCCN guidelines, considering factors that differentiate low-risk from high-risk PV.

Initial Treatment Strategies for Polycythemia Vera

Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which inform their treatment decisions for patients with PV.

Cytoreductive Therapy in PV Treatment Paradigm 

Panelists discuss the role of JAK inhibition in the treatment of polycythemia vera (PV), focusing on the latest efficacy data for ruxolitinib (RUX) from studies such as RUX vs best available therapy (BAT) in PV and the MAJIC-PV trial, highlighting its impact on treatment outcomes.

Panelists discuss additional data supporting the use of alternative agents and treatment pathways for polycythemia vera (PV), including the role of ropeginterferon alfa-2b (Ropeg alfa-2b) based on findings from the PROUD-PV /CONTINUATION-PV studies.

Interferon Therapy in PV

Panelists discuss the safety profiles of therapies for polycythemia vera (PV) and the safety considerations they take into account when determining which patients are best suited for these treatments.

Safety Considerations for PV Therapy

Panelists discuss how their treatment approach has evolved based on the efficacy and safety profiles from recent trials, how updated data align with or challenge NCCN Guidelines, and the clinical implications of real-world evidence. Dr Harrison explores treatment patterns, blood count control, and the decision to switch from hydroxyurea (HU) to ruxolitinib (RUX) therapy in polycythemia vera (PV).

Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence

Panelists discuss real-world treatment patterns for ropeginterferon alfa-2b (Ropeg alfa-2b) in the management of polycythemia vera (PV).

Interferon Real- World Treatment Patterns in PV 

Panelists discuss monitoring parameters when treating patients with polycythemia vera (PV), including what to assess, typical outcomes, and when treatment should be switched due to ineffectiveness. Dr Kuykendall to Dr Gangat: Panelists explore the risk of PV progression/transformation, risk factors for progression, and how the data influence patient care and treatment choices in practice.

JAK Inhibition in Polycythemia Vera: Treatment Updates

EP: 1.Initial Treatment Strategies for Polycythemia Vera

EP: 2.Cytoreductive Therapy in PV Treatment Paradigm

EP: 3.JAK Inhibition in Polycythemia Vera: Treatment Updates

EP: 4.Interferon Therapy in PV

EP: 5.Safety Considerations for PV Therapy

EP: 6.Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence

EP: 7.Interferon Real- World Treatment Patterns in PV

EP: 8.Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks

Latest Conference Coverage